Experimental Ebola Drug Trial Halted In Sierra Leone As ‘Predefined Statistical Endpoint’ Reached

New York Times: Clinical Trial of Experimental Ebola Drug Is Halted
“In a setback for efforts to combat Ebola, an experimental drug that researchers had considered one of the most promising potential treatments has not worked in patients in Sierra Leone, the drug’s developer said Friday…” (Pollack, 6/19).

ScienceInsider: In setback for potential Ebola drug, company halts trial
“…The company that developed the drug, Tekmira Pharmaceuticals of Burnaby, Canada, and the Wellcome Trust, which sponsored the trial, announced [Friday] that they would not enroll any more patients because the trial had reached ‘a predefined statistical endpoint.’ Early results suggest that adding more patients to the study ‘was unlikely to demonstrate an overall therapeutic benefit to patients,’ the Wellcome Trust said in its statement…” (Vogel/Kupferschmidt, 6/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.